Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe
This response plan is designed to prevent the spread of multidrug-resistant Neisseria gonorrhoeae (MDR NG) in the EU/EEA in the context of the possible emergence of untreatable gonorrhoea
Molecular typing of Neisseria gonorrhoeae
In 2011, a pilot study was undertaken to assess the public health benefit of molecular surveillance for gonorrhoea in 21 EU/EEA countries. A total of 1 066 isolates collected under the 2010 European gonococcal antimicrobial surveillance programme were typed and 406 sequence types identified, with considerable diversity among countries.
Annual Epidemiological Report 2009 [2007 data]
This edition of the Annual Report gives special attention to vaccine-preventable diseases and immunisation programmesin the European Union (EU) and European Economic Area (EEA) countries. This edition was revised January and June 2010 and has authority over the print edition.
- Antimicrobial resistance
- Avian influenza virus
- Emerging disease
- Food- and waterborne diseases
- Healthcare-associated infections
- HIV infection
- Influenza in humans, avian origin
- Influenza in humans, seasonal
- Sexually transmitted infections
- Vaccine preventable diseases
- Vector-borne disease
31st Congress of IUSTI-Europe on Sexually Transmitted Infections
The 31st IUSTI (International Union Against Sexually Transmitted Infections) Europe Congress addressed the broad range of science and clinical practice in the field of sexually transmitted infections.
ECDC: first detected cases of extensively drug-resistant gonorrhoea threaten future treatment
Within a matter of weeks, three cases of gonorrhoea that are resistant to the recommended first line antibiotic treatment have been detected in Europe and Australia. These are the first global reports of Neisseria gonorrhoeae with high-level resistance to azithromycin and ceftriaxone resistance that also show resistance to several other vital antibiotics. At a time with limited alternatives to the current dual therapy, lack of a vaccine and insufficient surveillance capacity in some regions, these cases highlight the growing threat of drug-resistance – which could lead to untreatable gonorrhoea.
Rapid Risk Assessment: Extensively drug-resistant (XDR) Neisseria gonorrhoeae in the United Kingdom and Australia
This rapid risk assessment aims to assess the risk of XDR Neisseria gonorrhoeae spreading further in the EU/EEA and provide some options for response.
Drug-resistance of gonorrhoea in the EU: persistent but stable
Neisseria gonorrhoea continues to show high levels of resistance to azithromycin across the European Union and European Economic Area, according to the 2016 results of the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP).
Call for scientific collaboration to support genomic-based surveillance of Neisseria gonorrhoeae-antimicrobial resistance at EU-level
ECDC is looking to establish a scientific collaboration with an organisation which can perform whole genome sequencing (WGS) of Neisseria gonorrhoeae, carry out related data analyses, share results of the analyses with ECDC and the participants of the European Gonococcal Antimicrobial Surveillance Programme as well as visualise the results.
Extensively drug-resistant gonorrhoea: risk of further dissemination within and across Europe
ECDC comment on the study 'Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018' by Eyre et al. in the Eurosurveillance edition of 7 March 2019.